WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, IARC, 2017
[2]
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2016
[3]
NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia, Version 2.2024
[4]
Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic lymphoma in adults: current practice and future perspectives. Ann Oncol. 2016;27(5):778-784
[5]
Larson RA. Management of acute lymphoblastic leukemia in older adults. J Geriatr Oncol. 2016;7(4):257-264
[6]
Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017;3(7):e170580
[7]
Ma H, Sun H, Sun X. Survival improvement by decade of age among acute lymphoblastic leukemia patients in Shanghai, China. Ann Hematol. 2016;95(1):133-142
[8]
Gökbuget N, Stanelle M, Hüttmann A, et al. Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are results preserved in adult patients aged 15-25 years? Haematologica. 2016;101(4):e141-e144
[9]
DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526-534
[10]
Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938-2948